The ASO inhibited neuropeptide Y1 receptor expression in rats and increased anxiety. This may represent a proof of concept that psychopathological features can be modulated by an ASO strategy. Brain-derived neurotrophic factor (BDNF) may pose another target, considering its pivotal role in neuroplasticity, network formation, and cognition. 14 An ASO that binds on BDNF natural antisense transcripts increased BDNF mRNA levels 2-to 7-fold along with neuronal outgrowth in vitro and in vivo. 15 Another target may be the dopamine receptor (DR). In 1993, an ASO targeting DR2 mRNA successfully reduced striatal DR2 in rats. 16 Despite the encouraging progress in ASO strategies, the introduction of ASOs in psychiatry is lagging far behind to those investigated or even approved in neurological disorders. There are still many hurdles to overcome to improve diagnostics and treatment options. A first major challenge is to link molecular and cellular alterations to changes at the genome level. Second, molecular, cellular, and biochemical changes still have to be defined and associated with each disorder. 17 Although no safety concerns were identified for most of the currently available ASOs, 1, 3 off-target effects may further limit the widespread ASO utilization, particularly in psychiatry. For example, a chronic overexpression of BDNF impaired learning and memory in mice. 18 However, there is no need for pessimism considering that the encouraging approaches as shown for SMA or AD were barely conceivable only a few years ago. As provided by ASOs, the perspective of efficient treatment could be a driving force in the inevitable necessary basic research in psychiatric disorders that may yield in introducing ASO strategies in this field in the future.
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INFORMATION Heiko Graf declares that he has no potential conflicts of interest or financial disclosures. Claudia Diana Wurster has received travel expenses for attending a meeting from Biogen, and she cooperates with Hoffmann-La Roche. 2 Acetazolamide is indicated for centrencephalic epilepsies, idiopathic intracranial hypertension, secondary glaucoma, and preoperatively in acute angle closure glaucoma where delay of surgery is desired to lower intraocular pressure.
2 It appears to have beneficial effect in psychogenic polydipsia. 3 Common adverse effects of acetazolamide include tingling, palinopsia, dizziness, diuresis, tiredness, confusion, anorexia, and weight loss. One of the common adverse effects of the antipsychotic drugs is weight gain and metabolic adverse effects. 4 Given the treatment compliance associated with weight gain and obesity, clinicians should monitor weight during the course of antipsychotic therapy and consider switching agents if excessive weight gain occurs. 5 Body weight and metabolic risk profile in patients receiving atypical antipsychotic medications need to be effectively managed with a weight control program including physical activity, which is difficult in illness such as schizophrenia. 6 Topiramate is an anticonvulsant that reportedly confers weight loss in patients receiving doses up to 300 mg/d. 7 Topiramate appears to inhibit specific carbonic anhydrase enzymes II and V compared with azetazolamide, which is a nonspecific inhibitor of carbonic anhydrase enzymes and has been demonstrated to decrease lipogenesis in adipose cells in vitro cell culture studies. 1 Zonisamide, another antiepileptic drug, also a carbonic anhydrase inhibitor, 8 is known to cause weight loss in adolescents 9 and adults. 10 Patients with idiopathic intracranial hypertension and mild visual loss assigned to either acetazolamide or placebo, all of whom received a 6-month telephone-based weight loss intervention, lost an average of 5.9% of initial body weight, consistent with the NHLBI (National Heart Lung and Blood Institute) guidelines of 5% to 10% of body weight loss for clinically significant health benefit. 11 Ophthalmologists have concerns that acetazolamide retards weight gain when given to children. In a retrospective chart review, 22 well children with glaucoma taking oral acetazolamide for 3 months or more showed poor weight gain in a small subset of children. 12 Fifteen consecutive female patients with idiopathic intracranial hypertension associated with obesity were studied to determine the weight loss associated with resolution of papilloedema. Patients underwent weight loss on treatment with acetazolamide during the 24-week period. Weight loss of 3.3%±0.5% (mild) was observed among patients having a 1-grade change in papilloedema and 6.2% ± 0.6% was associated with a 3-grade (marked) change in papilloedema. Approximately 6% weight loss was associated with resolution of marked papilloedema in these patients. 13 A young obese lady gained significant weight after commencing risperidone and later developed headache and blurred vision. She was diagnosed to have benign intracranial hypertension due to risperidone usage. Withdrawing the offending drug and addition of acetazolamide 500 mg twice daily (given for benign intracranial hypertension) led to weight loss and drastically improved her symptoms within a month. Acetazolamide probably helped in recovery by diuresis.
14 A 49-year-old obese patient who was started on acetazolamide 250-mg twice daily had significant weight loss of 11.5 lb (5.21 kg) over 4 weeks similar to topiramate. 1 In a study, when acetazolamide was given to 30 patients of which puberal periodic psychosis (6 cases), presenile atypical psychosis (7 cases), atypical psychosis (8 cases), atypical manic-depressive psychosis (2 cases), and atypical schizophrenia (7 cases), some extent of therapeutic effects of acetazolamide (500-1000 mg) as an antipsychotic was obtained in approximately 70% of the patients. High therapeutic effects were particularly observed in puberal periodic psychosis, presenile atypical psychosis, and atypical psychosis. Acetazolamide showed effectiveness in 10 of the 13 cases to which lithium carbonate and carbamazepine were ineffective. Acetazolamide was considered to have antipsychotic and prophylactic effects on atypical psychosis. Adverse effects were rarely observed in the study, and acetazolamide had a high safety margin. 15 Twenty-four chronic schizophrenia patients were treated successfully with the addition of acetazolamide plus thiamine to their unchanged existing therapies in a double-blind, placebo-controlled cross-over study. Therapeutic effects were measured by the scale for the assessment of positive symptoms and the scale for the assessment of negative symptoms. Overall 50% of the patients showed improvement on all the assessment scales. 16 
CONCLUSIONS
Several clinical studies have reported weight loss as an adverse effect of acetazolamide, and it has shown some beneficial effects in treating psychosis (hence no risk of increasing the primary illness). We conclude, based on the associated weight loss and the apparent improvement in psychotic symptoms, that randomized controlled clinical trials of acetazolamide in antipsychotic-related weight gain are indicated to confirm the associations.
